Startups channel feed

Lati­go, a pain biotech years in the mak­ing, emerges with $135M on heels of Ver­tex PhI­II suc­cess

Last year
Financing

Eu­ro­pean in­vestor Early­bird Health clos­es $185M fund to back 12 to 15 com­pa­nies

Last year
Financing

Lian­Bio to shut­ter, end­ing Shang­hai-based start­up’s transat­lantic am­bi­tions

Last year
People
China

BioAge rais­es $170M as obe­si­ty spot­light shifts to oral op­tions, mus­cle pre­servers

Last year
Financing

Seat­tle biotech found­ed by for­mer Seagen lead­ers nabs $112M for three clin­i­cal-stage AD­Cs

Last year
Financing
China

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Last year
Financing

Ex­clu­sive: In­clud­ed Health makes lay­offs as CEO tar­gets ‘nar­row­er’ lead­er­ship, staff and spend­ing

Last year
Health Tech

Pre­clin­i­cal biotech Metageno­mi prices $94M IPO at low end of pro­posed range

Last year
Financing
Cell/Gene Tx

Neu­rona rais­es $120M to take epilep­sy cell ther­a­py to late-stage de­vel­op­ment

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: Men­tal health start­up Head­light rais­es $18M in a round backed by Pill­Pack co­founder TJ Park­er

Last year
Health Tech

Kyver­na lands $319M IPO as au­toim­mune CAR-T field has its mo­ment in the sun

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: Top neu­ro­sci­en­tist Asa Abe­liovich tar­gets ALS, schiz­o­phre­nia with new start­up Leal af­ter $1B Lil­ly buy­out

Last year

A new VC fund emerges with $310M to cre­ate in­de­pen­dent, com­mer­cial biotechs

Last year
Financing

ARCH, one of life sci­ences' pre­mier in­vestors, eyes $3B for 13th fund

Last year
Financing

Al­to Neu­ro­science and Fractyl Health add to biotech IPO mo­men­tum in Fri­day dou­ble­head­er

Last year
Financing

Ex­clu­sive: Col­umn Group rais­es a new $400M+ fund and R&D hub for sin­gle-as­set bi­o­log­ics com­pa­nies

Last year
Financing

The aca­d­e­m­ic-en­tre­pre­neur mod­el built com­pa­nies and mint­ed mil­lion­aires. What hap­pens when one of its ear­li­est ad­vo­cates quits?  

Last year
People
In Focus

Avro­bio makes way for GPCR biotech Tec­ton­ic Ther­a­peu­tic in re­verse merg­er

Last year
Deals
Cell/Gene Tx

Chica­go-area au­toim­mune biotech gets phar­ma back­ing in $105M round for two PhII tri­als

Last year
Financing

Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Last year
Financing

De­cen­tral­ized tri­als com­pa­ny Sci­ence 37 to go pri­vate in deal with di­ag­nos­tics start­up eMed

Last year
Deals

LB Phar­ma­ceu­ti­cals clos­es $75M Se­ries C as it be­gins PhII schiz­o­phre­nia tri­al

Last year
Financing

Ex­clu­sive: Reid Hu­ber re­unites with for­mer In­cyte col­league Wen­qing Yao, backs Syn­no­va­tion with $102M for three tri­als

Last year
Financing

Gene edit­ing de­liv­ery biotech GenEd­it part­ners with Genen­tech, rais­es an­oth­er $24M

Last year
Financing
Pharma
First page Previous page 19202122232425 Next page Last page
A service from the Financial Times